ArticlePloS one2026
Labeling matters: A multicenter machine learning study on visual field progression in Glaucoma.
Article in PloS one, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundTo compare machine learning (ML) performance for detecting visual field (VF) progression across different labeling strategies using a large multicenter dataset.
methodsIn this multicenter retrospective study, VF data were collected from five tertiary referral hospitals. Two algorithm-derived labeling approaches were evaluated without an independent clinical reference standard: an inclusive Consensus label, defined as progression detected by at least one of five conventional algorithms (mean deviation slope, Visual Field Index slope, Advanced Glaucoma Intervention Study, Collaborative Initial Glaucoma Treatment Study, and pointwise linear regression), and a conservative Wiggs' label, based on a region-based event-threshold rule. Four ML classifiers, support vector machine, random forest, logistic regression, and extreme gradient boosting, were trained using each labeling strategy. Model performance was assessed using the area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and precision-recall analysis summarized by average precision (AP).
resultsUsing the Consensus label, all models demonstrated excellent discrimination (AUC, 0.92-0.95), with high sensitivity (0.82-0.85) and near-perfect specificity (0.99-1.00). Precision-recall analysis showed consistently high reliability of progression detection, with AP values ranging from 0.93 to 0.94. In contrast, models trained with the Wiggs' label exhibited lower AUCs (0.88-0.89) and reduced sensitivity (0.63-0.72), while maintaining moderate-to-high specificity (0.87-0.92) and lower AP values (0.84-0.85), reflecting a stricter, region-based progression definition. Ablation analysis showed that Consensus-based performance was not driven by any single criterion, but rather by complementary information across heterogeneous progression algorithms.
conclusionIn this multicenter study, the labeling strategy was a major determinant of ML performance in VF progression detection. The Consensus label enabled sensitive and reliable identification of progression with high specificity with respect to the Consensus label definition across heterogeneous clinical settings, whereas the Wiggs' label provided conservative, spatially consistent confirmation. The observed performance differences primarily reflect model-label compatibility rather than the clinical validity of either detection system, underscoring that careful definition of ground truth is critical for interpreting ML-based glaucoma progression research.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.